What we achieved in 2025, together
Date
Research news
Date
Lixisenatide, a diabetes drug being investigated for Parkinson’s, shows potential to slow the progression of movement symptoms.
Date
New research study shows impact of delirium for people with Parkinson’s in hospital
Date
The simple skin test was able to detect a troublesome protein associated with Parkinson's and other similar conditions.
Date
Our latest round of grants fund projects which aim to improve everyday life for people living with Parkinson’s, without the need for extra medications.
Date
Foslevodopa-foscarbidopa (also called Produodopa) has been approved by NICE in England, Northern Ireland and Wales and the Scottish Medicines Consortium for people with Parkinson’s who experience movement related symptoms.
Date
Foslevodopa-foscarbidopa (also called Produodopa) can be offered in England from 27 February for people with Parkinson’s who experience movement related symptoms.
Date
A further trial of a device-delivered GDNF is not going ahead, but other approaches are showing promise.
Date
Predict-PD is a study that aims to understand the risk factors of Parkinson’s. More than 10,000 people are now taking part and are representative of the ethnic diversity within the UK population.
Date
Leading scientists and patient organisations have worked together to develop a framework for using 2 tests to identify Parkinson’s in clinical trials.
Date
In 2023 Parkinson’s UK campaigners and staff took action on the cost of living crisis, increasing the health and care workforce, and improving the benefits system and time critical medication administration in hospitals